Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allakos Inc ALLK

Healthcare Biotechnology
Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Company’s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively... see more

Recent & Breaking News (NDAQ:ALLK)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allakos Inc. - ALLK

PR Newswire January 6, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allakos Inc. - ALLK

GlobeNewswire January 3, 2020

Glancy Prongay & Murray LLP Continues Its Investigation on Behalf of Allakos Inc. Investors

Business Wire January 3, 2020

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Allakos Inc. Investors

Business Wire January 3, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allakos Inc. - ALLK

ACCESSWIRE IA December 21, 2019

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Allakos (ALLK) Investors with Significant Losses to Contact Its Attorneys; Firm Investigating Possible Securities Fraud

PR Newswire December 19, 2019

ALLAKOS ALERT: Bragar Eagel & Squire, P.C. is Investigating Allakos, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm

Business Wire December 19, 2019

Glancy Prongay & Murray LLP Announces Investigation on Behalf of Allakos Inc. Investors

Business Wire December 19, 2019

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Allakos Inc. Investors

Business Wire December 19, 2019

ALLK LOSSES ALERT: Bernstein Liebhard LLP Reminds Investors of its Investigation of Allakos Inc.

PR Newswire December 19, 2019

Allakos, Inc. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

GlobeNewswire December 19, 2019

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Allakos Inc. (ALLK)

ACCESSWIRE IA December 19, 2019

ALLK LOSSES ALERT: Bernstein Liebhard LLP Announces an Investigation of Allakos Inc.

Business Wire December 18, 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allakos Inc. - ALLK

GlobeNewswire December 18, 2019

Allakos Reports Third Quarter 2019 Financial Results

GlobeNewswire November 12, 2019

Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting

GlobeNewswire October 28, 2019

Allakos Announces Upsizing and Pricing of Public Offering of Common Stock

GlobeNewswire August 6, 2019

Allakos Announces Proposed Public Offering of Common Stock

GlobeNewswire August 5, 2019

Allakos Reports Second Quarter 2019 Financial Results

GlobeNewswire August 5, 2019

Allakos Announces AK002 Met All Prespecified Primary and Secondary Endpoints in Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE)

GlobeNewswire August 5, 2019